Monte Rosa Therapeutics, Inc. Common Stock

GLUENASDAQ • USD
ThemeBiotech - Drug Development›Clinical-Stage Platforms
14.37 USD
↘ 0.18 (1.24%)🔴AT CLOSE (AS OF 07:31 PM EDT)
🔴Market: CLOSED

Shares of Monte Rosa Therapeutics, Inc. Common Stock (GLUE) are trading at $14.37. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". Key drivers include a weak Piotroski F-Score of 1/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. GLUE is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Aug 26, 2026.

Open?$14.44
High?$14.62
Low?$14.10
Prev. Close?$14.56
Volume?997.7K
Avg. Volume?1.4M
VWAP?$14.28
Rel. Volume?0.73x
Bid / Ask
Bid?$12.21 × 100
Ask?$16.64 × 100
Spread?$4.43
Midpoint?$14.43
Valuation & Ratios
Market Cap?1.2B
Shares Out?85.3M
Float?49.3M
Float %?75.7%
P/E Ratio?N/A
P/B Ratio?2.55
EPS?-$1.89
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Themes
Biotech - Drug Development›Clinical-Stage PlatformsHealthcare - Oncology›Targeted Therapy & Precision OncologyAI & Machine Learning›AI-Powered Analytics & Decision Systems
Employees
173
Market Cap
1.2B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.monterosatx.com
Listed
2021-06-24
Address
321 HARRISON AVENUE
BOSTON, MA 02118
Phone: 617-949-2643
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
60
Momentum?
50
Short Sent.?
25
Piotroski F-Score?1/9Weak
Altman Z-Score?2.68Grey
Confidence?61%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?35.40%Squeeze Risk
Short Interest?17.5M
Days to Cover?14.0
Free Float49.3M
Avg Daily Volume1.2M
Settlement Date2026-08-14
Financial Health
Current Ratio?10.58Strong
Quick Ratio?10.58Strong
Cash Ratio?1.51Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
63
2.55CHEAP▾
P/S?
Peers
100
S&P
3
43.24HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-6.6CHEAP▾
EV/Sales?
Peers
100
S&P
3
40.10HIGH▾
Returns & Efficiency
ROE?
S&P
6
-33.1%WEAK▾
ROA?
S&P
3
-23.3%WEAK▾
Cash Flow & Enterprise
FCF?$-32078000
Enterprise Value?$1.2B
Fundamentals ratios updated end of day
MarketsMoversWatchlist